Engineering the Future of Targeted Protein Degradation and Precision Delivery
At Nanomedsyn, we develop AMFA glycovectors designed to target the mannose 6 phosphate receptor (M6PR) to enable precise intracellular delivery and selective lysosomal degradation of toxic disease‑driving antigens.
By exploiting endogenous M6PR‑mediated trafficking, our technology creates new mechanisms of action for major therapeutic classes:
- Therapeutic antibodies transformed into first‑in‑class degraders, capable of selectively degrading the toxic antigen while being recycled instead of degraded.
- Therapeutic nanoparticles rerouted to extra‑hepatic tissues, expanding the reach of RNA, enzymes, and biologics.
- Optimized lysosomal delivery for ERT in rare diseases.
By unlocking controlled intracellular routing, we open new frontiers in drug discovery once considered inaccessible.
We collaborate with pharmaceuticals companies, biotech, and academic partners to develop breakthrough medicines. Together, we are shaping the future of targeted degradation and precision therapeutics.
AMFA Glycovectors Platform
AMFA glycovectors are synthetic sugar‑based ligands engineered to:
- Increase receptor‑specific cellular uptake through M6PR binding
- Promote efficient endosomal progression and lysosomal trafficking
- Drive selective lysosomal degradation of cargo‑bound antigens
- Deliver antibodies, enzymes, RNA, or nanoparticle formulations
- Modify biodistribution and bypass hepatic sequestration
The platform can be adapted to multiple therapeutic formats.
Therapeutic Antibodies as First‑in‑Class Targeted Degraders
NanoMedSyn creates a new generation of antibodies capable of destroying—not merely inhibiting—disease‑critical proteins.
Our glycovector technology allows:
- Selective internalization of the antibody–antigen complex
- Recycling of the antibody to the cell exterior, avoiding lysosomal degradation
- Specific degradation of the toxic antigen alone
This approach transforms classical antibodies into Targeted Protein Degraders (TPD) using a unique M6PR‑based mechanism.
Nanoparticles for Precision Delivery (AMFA‑NP)
Our technology remodels therapeutic nanoparticles to achieve:
- Targeted extra‑hepatic distribution
- Improved cellular uptake
- Access to previously restricted tissues
- Efficient lysosomal delivery of mRNA, RNA, enzymes, and biologics
Enhanced Enzyme Replacement Therapy (ERT)
AMFA‑engineered enzymes achieve:
- Improved lysosomal targeting
- Broader tissue penetration beyond the liver
- Increased stability and durability of therapeutic effect
This enables next‑generation treatments for rare lysosomal disorders such as Pompe disease.
